- Home
- MTEK vs IMNN Comparison
MTEK vs IMNN Comparison
Compare MTEK & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- IMNN
- Stock Information
- Founded
- MTEK 2008
- IMNN 1982
- Country
- MTEK Israel
- IMNN United States
- Employees
- MTEK N/A
- IMNN N/A
- Industry
- MTEK
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- IMNN Health Care
- Exchange
- MTEK Nasdaq
- IMNN Nasdaq
- Market Cap
- MTEK 24.0M
- IMNN 12.1M
- IPO Year
- MTEK 2022
- IMNN 1985
- Fundamental
- Price
- MTEK $3.46
- IMNN $5.42
- Analyst Decision
- MTEK
- IMNN Buy
- Analyst Count
- MTEK 0
- IMNN 2
- Target Price
- MTEK N/A
- IMNN $182.61
- AVG Volume (30 Days)
- MTEK 105.0K
- IMNN 54.7K
- Earning Date
- MTEK 09-05-2025
- IMNN 11-06-2025
- Dividend Yield
- MTEK N/A
- IMNN N/A
- EPS Growth
- MTEK N/A
- IMNN N/A
- EPS
- MTEK N/A
- IMNN N/A
- Revenue
- MTEK $6,078,953.00
- IMNN N/A
- Revenue This Year
- MTEK N/A
- IMNN N/A
- Revenue Next Year
- MTEK N/A
- IMNN N/A
- P/E Ratio
- MTEK N/A
- IMNN N/A
- Revenue Growth
- MTEK 50.80
- IMNN N/A
- 52 Week Low
- MTEK $1.63
- IMNN $4.83
- 52 Week High
- MTEK $6.47
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- MTEK 64.08
- IMNN 48.06
- Support Level
- MTEK $3.06
- IMNN N/A
- Resistance Level
- MTEK $3.32
- IMNN $5.89
- Average True Range (ATR)
- MTEK 0.29
- IMNN 0.30
- MACD
- MTEK 0.07
- IMNN -0.15
- Stochastic Oscillator
- MTEK 86.41
- IMNN 84.82
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).